Genmab — Januar 2021

[JørgenVarnæs]

husk at "gøre rent" for specifikke events - vi fik f.eks. godkendelser af covid vacciner i den periode

[Solsen]

CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
Company Announcement

Novartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of multiple sclerosis

Opinion based on Phase 3 ASCLEPIOS I and II studies

[JørgenVarnæs]

smukt - så en måneds tid og vi er i mål

[GeorgeBest]

[Klarussen]

Jeg savner Trump, der var ligesom mere styr og
fokus på aktiekurserne.

[Darvin]

Men dejligt at se - Novartis får god anbefaling af Ofatumumab fra ekspertpanel

[Darvin]

https://ir.genmab.com/news-releases/news-release-details/chmp-issues-positive-opinion-recommending-ofatumumab-relapsing

[Darvin]

Som Sollsen så smukt skrev - blot et link

[Bulder]

Så kan EU også nå at bidrage, når salget kommer op at køre i H2.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

Amivantamab ( chrysalis ) https://www.onclive.com/view/dr-sabari-on-the-updated-results-of-the-chrysalis-study-with-amivantamab-in-egfr-nsclc?utm_source=sfmc&utm_medium=email&utm_campaign=1-29-21_AST-20-OSD0982_OncLiveSS_ GLOBAL WCLC Conference Coverage eNL_Tagrisso_1&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[Doublo]

God formiddag...er faren for en bund længere nede drevet over for denne gang? hvad siger TA

[Doublo]

Øver mig i at huske forkortelserne men har ikke helt styr på hvad NBI betyder?

[Klarussen]

@Doublo: det eneste sikre her i livet er bedemanden og skattefar. Der er ingen 100% sikkerhed i aktiemarkedet, heller ikke bunden for Genmab-kursen. Synes dog fremtiden for Genmab ser fornuftig ud på længere sigt, men meget kan ske både for Genmab og aktiemarkedet generelt.

[Doublo]

Klarussen jeg efterlyser ikke garantier men tendenser, vi har før fået fine TA-link

[Doublo]

tak for link Pensionisten

[E_L]

Sabari was confident enough in amivantamab’s data to take a swipe at mobocertinib, saying the Takeda program matched up poorly on safety given Thursday’s results.

“The data, to me, that’s been publicly available does not look as good as the data for amivantamab, and unfortunately with their TKI you see a lot of wild-type EGFR inhibition tox[icity] like diarrhea and rash, which you don’t see as commonly with amivantamab,” Sabari said.

[E_L]

https://endpts.com/jj-pushes-new-amivantamab-data-for-nsclc-subset-trying-to-bolster-case-for-quick-fda-approval/

[Helge_LarsenPI-redaktør]

Genmab: HexaBody https://www.proinvestor.com/index.php?p=debat_1&postid=90339

[E_L]

BlackRock funds @ 7.3% https://ir.genmab.com/node/39786/html
https://ir.genmab.com/stock-information/major-shareholders#content